ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial.

Lee J, Dean A, Price T, Sjoquist K, Gebski V, Mumford J, Day F, Yip S, Wilson K, Jackson C, Padinharakam S, Lee B, Burge M, Siu D, Karapetis C, Chantrill L, Wong ZW, Jennens R, Lomma C, Franscesconi A, Ackland S, Lynam J, Wahlroos S, So J, Jameson M, Tebbutt N, Gill S, Grimes D, Steer C, Harris M

Open source

DOI: 10.1016/j.esmogo.2023.07.001
Published: 2023 Oct
Container: ESMO gastrointestinal oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmogo.2023.07.001,
  title = {ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial.},
  author = {Lee J and Dean A and Price T and Sjoquist K and Gebski V and Mumford J and Day F and Yip S and Wilson K and Jackson C and Padinharakam S and Lee B and Burge M and Siu D and Karapetis C and Chantrill L and Wong ZW and Jennens R and Lomma C and Franscesconi A and Ackland S and Lynam J and Wahlroos S and So J and Jameson M and Tebbutt N and Gill S and Grimes D and Steer C and Harris M},
  year = {2023},
  journal = {ESMO gastrointestinal oncology},
  doi = {10.1016/j.esmogo.2023.07.001},
  url = {https://doi.org/10.1016/j.esmogo.2023.07.001}
}

RIS

TY  - JOUR
TI  - ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial.
AU  - Lee J
AU  - Dean A
AU  - Price T
AU  - Sjoquist K
AU  - Gebski V
AU  - Mumford J
AU  - Day F
AU  - Yip S
AU  - Wilson K
AU  - Jackson C
AU  - Padinharakam S
AU  - Lee B
AU  - Burge M
AU  - Siu D
AU  - Karapetis C
AU  - Chantrill L
AU  - Wong ZW
AU  - Jennens R
AU  - Lomma C
AU  - Franscesconi A
AU  - Ackland S
AU  - Lynam J
AU  - Wahlroos S
AU  - So J
AU  - Jameson M
AU  - Tebbutt N
AU  - Gill S
AU  - Grimes D
AU  - Steer C
AU  - Harris M
PY  - 2023
JO  - ESMO gastrointestinal oncology
DO  - 10.1016/j.esmogo.2023.07.001
UR  - https://doi.org/10.1016/j.esmogo.2023.07.001
ER  -

APA

J, L., A, D., T, P., K, S., V, G., J, M., F, D., S, Y., K, W., C, J., S, P., B, L., M, B., D, S., C, K., L, C., ZW, W., R, J., C, L., A, F., S, A., J, L., S, W., J, S., M, J., N, T., S, G., D, G., C, S., & M, H. (2023). ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial.. ESMO gastrointestinal oncology. https://doi.org/10.1016/j.esmogo.2023.07.001

Source records

pubmed · retrieved 2026-09-27T07:05:56.593Z